EUVIMEDEUVIMED entdecken
Crossref

Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice

Elizabeth O Ferreira iD, Alexandra M Schefter, Abby Brustad, Molly E Klein, Mahmoud A Khalifa, Boris Winterhoff, Andrew C Nelson iD

American Journal of Clinical Pathology · 2024

DOI: 10.1093/ajcp/aqae010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Elizabeth O Ferreira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We sought to confirm utility of our institution’s modified Proactive Molecular Risk Classifier for Endometrial Cancer protocol in our daily practice, which includes mismatch repair (MMR), p53, and L1 cell adhesion molecule (L1CAM) immunohistochemistry with in-house next-generation sequencing for POLE, TP53, and CTNNB1.

Methods

We conducted a retrospective review of all patients in our institution who underwent primary endometrial carcinoma resection from the year prior to protocol implementation (PRE; October 1, 2020, to September 30, 2021) through first year of implementation (POST; October 1, 2021, to September 30, 2022) to compare the distribution of molecular and traditional staging factors using GOG-249 criteria to assign clinical risk.

Results

In total, 136 of 260 PRE patients were classified as clinically low risk (LR), of whom 31 were MMR deficient. Of the 157 LR POST patients with endometrioid-type carcinoma, 45 were MMR deficient, 5 were POLE mutant, 5 were TP53 mutant, 56 were of no specific molecular profile (NSMP), and 46 did not receive full protocol testing. Of all 79 POST NSMP endometrioid-type cases, 18 were CTNNB1 mutated and 8 showed L1CAM expression.

Conclusions

Our protocol identified 22 (14%) of 157 LR tumors that harbored incipient intermediate- to high-risk molecular aberrations in TP53, CTNNB1, or L1CAM. Moving forward, results of ongoing trials assessing adjuvant therapy decisions based on molecular classification are necessary to confirm protocol utility and identify appropriate modifications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsTumor Suppressor Protein p53HumansFemaleRetrospective StudiesMiddle AgedAgedBiomarkers, TumorDNA Mismatch Repairbeta CateninImmunohistochemistryAdultHigh-Throughput Nucleotide SequencingAged, 80 and overNeural Cell Adhesion Molecule L1Carcinoma, Endometrioid

Stichwörter der Autor:innen

ProMisE Proactive Molecular Risk Classifier for Endometrial Cancerbiomarkersendometrial cancermolecular profilingnext-generation sequencing

Substanzen

Tumor Suppressor Protein p53Biomarkers, TumorCTNNB1 protein, humanbeta CateninTP53 protein, humanNeural Cell Adhesion Molecule L1

Autor:innen und Institutionen

  • Department of Pathology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
  • Department of Obstetrics, Gynecology and Women's Health, Minneapolis, MN, US.
  • University of Minnesota Medical School, Minneapolis, MN, US.
  • Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, US.

ORCID-Profile: Elizabeth O Ferreira, Andrew C Nelson

Zitieren

APA

Ferreira, E. O., Schefter, A. M., Brustad, A., Klein, M. E., Khalifa, M. A., Winterhoff, B., & Nelson, A. C. (2024). Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae010

Vancouver

Ferreira EO, Schefter AM, Brustad A, Klein ME, Khalifa MA, Winterhoff B, et al. Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqae010

BibTeX
@article{Ferreira2024,
  author = {Ferreira, Elizabeth O and Schefter, Alexandra M and Brustad, Abby and Klein, Molly E and Khalifa, Mahmoud A and Winterhoff, Boris and Nelson, Andrew C},
  title = {Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  doi = {10.1093/ajcp/aqae010}
}
Kostenlos starten →